口服重组甲硫氨酸酶可预防高脂饮食诱导的小鼠非酒精性脂肪肝病。
Oral Recombinant Methioninase Prevents Nonalcoholic Fatty Liver Disease in Mice on a High Fat Diet.
机构信息
AntiCancer Inc, San Diego, CA, U.S.A.
Department of General and Gastroenterological Surgery, Showa University School of Medicine, Tokyo, Japan.
出版信息
In Vivo. 2020 May-Jun;34(3):979-984. doi: 10.21873/invivo.11866.
BACKGROUND/AIM: We have recently shown that oral recombinant methionase (o-rMETase) prevents obesity and diabetes onset in mice on a high-fat (HF) diet. The present study aimed to determine if o-rMETase can inhibit the onset of nonalcoholic fatty liver disease (NAFLD) onset in mice on a high-fat diet.
MATERIALS AND METHODS
Male C57BL/6J mice in the control group were fed a normal-fat diet (NFD) (+6.5% fat), and other mice were fed a high-fat (HF) diet (+34.3% fat). Then, the mice on the HF diet were divided into two dietary groups: i) HF+phosphate buffered saline (PBS) group, and ii) HF+o-rMETase group.
RESULT
The fatty change score in the livers of mice treated with HF+PBS increased to an average of 2.6 during the experimental period of 8 weeks. In contrast, the fatty change in the livers of mice on the HF+o-rMETase group had an average score of 0.92 (p=0.04, HF+PBS vs HF+o-rMETase).
CONCLUSION
o-rMETase inhibited the onset of NAFLD as well as prevented obesity and the onset of diabetes on a high-fat diet, offering a possibility of a new paradigm to prevent liver cirrhosis or liver cancer via NAFLD.
背景/目的：我们最近发现，口服重组蛋氨酸酶（o-rMETase）可预防高脂肪（HF）饮食的肥胖和糖尿病的发生。本研究旨在确定 o-rMETase 是否可以抑制高脂肪饮食的小鼠中非酒精性脂肪性肝病（NAFLD）的发生。
材料和方法
对照组雄性 C57BL/6J 小鼠喂食正常脂肪饮食（NFD）（+6.5%脂肪），其他小鼠喂食高脂肪饮食（HF）（+34.3%脂肪）。然后，将 HF 饮食组的小鼠分为两组：i）HF+磷酸盐缓冲盐水（PBS）组，ii）HF+o-rMETase 组。
结果
在 8 周的实验期间，用 HF+PBS 治疗的小鼠肝脏中的脂肪变化评分增加到平均 2.6。相比之下，HF+o-rMETase 组的小鼠肝脏中的脂肪变化平均得分为 0.92（p=0.04，HF+PBS 与 HF+o-rMETase）。
结论
o-rMETase 抑制了 NAFLD 的发生，并预防了高脂肪饮食引起的肥胖和糖尿病的发生，为通过 NAFLD 预防肝硬化或肝癌提供了一种新的范式。
Zotero 插件